A Novel Ruthenium Antimicrobial Platform Technology - Preventing and Treating Multi-Drug Resistant Infections

MetalloBio是谢菲尔德大学的一家衍生公司，由克里斯蒂·斯米滕博士和吉姆·托马斯教授共同创立。MetalloBio正在开发一系列新的抗菌化合物。这些化合物正被开发为治疗呼吸道细菌感染的药物和防止医疗器械部位感染的医疗器械涂层。支撑该平台的化合物比目前的抗生素更具活性，具有新的作用机制，几乎不会出现耐药性，并代表了一种新的抗菌剂类别。客观地说，一种新的抗菌剂类别已经30多年没有进入临床了。抗菌剂正处于临床前开发阶段，涂层技术原型已经开发出来。该奖项加快了MetalloBio公司的技术开发，缩短了上市时间，将通过改善患者的生活质量和降低死亡率来实现最大影响。该项目将使MetalloBio公司能够完成潜在客户概述的关键临床前试验，包括对90种与呼吸道感染有关的细菌菌株进行广泛的抗菌素筛选。此外，它还将使该团队能够将抗菌剂的合成规模扩大到允许将其并入聚合物中用于商业应用的水平。最后，将与一家排名前十的医疗器械公司进行商业有效性研究，以确定这种聚合物是否可以用于覆盖他们的医疗器械技术。

MetalloBio is a University of Sheffield spin-out company co-founded by Dr Kirsty Smitten and Professor Jim Thomas. MetalloBio are developing a new series of antimicrobial compounds. The compounds are being developed as drugs to treat respiratory bacterial infections and as medical device coatings to prevent infections from developing at the medical device site.The compounds that underpin the platform are more active than current antibiotics, have a novel mechanism of action, little-to-no emergence of resistance and represent a new antimicrobial class. To put this into perspective a new antimicrobial class has not reached the clinic in over 30-years. The antimicrobial is in the preclinical stage of development and the coating technology prototype has been developed.This award accelerate MetalloBio's technology's development and reduce the time to the market, where maximum impact through improved patient quality of life and reduced death rates will be achieved. The project will allow MetalloBio to complete key preclinical experiments outlined by potential customers as essential, including a wide antimicrobial screen of 90 bacterial strains relevant to respiratory infections. Additionally, it will allow the team to scale the synthesis of the antimicrobials to a level that will allow incorporation into polymers for commercial applications. Finally, commercial validity will be studied with a top 10 medical device company, to determine if the polymer can be used to coat their medical device technology's.